clofazimine has been researched along with Body Weight in 4 studies
Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619)
clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The calculated relative systemic bioavailability (Frel) of CLF from the coevaporate, relative to that from Lamprene, was three." | 2.67 | Comparative bioavailability of clofazimine coevaporate in the pig. ( Abraham, I; Krishnan, TR, 1994) |
| " Weight-based dosing in patients <50 kg and ≥50 kg must be considered to achieve optimal treatment outcomes and reduce adverse events." | 1.56 | Dose-related treatment outcomes in South African patients prescribed clofazimine for drug-resistant tuberculosis. ( Misra, N; Naidoo, P; Padayatchi, N, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Misra, N | 1 |
| Padayatchi, N | 1 |
| Naidoo, P | 1 |
| Piubello, A | 1 |
| Harouna, SH | 1 |
| Souleymane, MB | 1 |
| Boukary, I | 1 |
| Morou, S | 1 |
| Daouda, M | 1 |
| Hanki, Y | 1 |
| Van Deun, A | 1 |
| O'Connor, R | 1 |
| O'Kennedy, R | 1 |
| James, P | 1 |
| Krishnan, TR | 1 |
| Abraham, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Culture Free Diagnosis and Follow-up of Multidrug Resistant Tuberculosis Patients[NCT03303963] | 3,356 participants (Actual) | Observational | 2017-05-04 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for clofazimine and Body Weight
| Article | Year |
|---|---|
Comparative bioavailability of clofazimine coevaporate in the pig.
Topics: Animals; Biological Availability; Body Weight; Chromatography, High Pressure Liquid; Clofazimine; Fe | 1994 |
3 other studies available for clofazimine and Body Weight
| Article | Year |
|---|---|
Dose-related treatment outcomes in South African patients prescribed clofazimine for drug-resistant tuberculosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Body Weight; Clofazimine; Cohort | 2020 |
High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses.
Topics: Adolescent; Adult; Aged; Body Mass Index; Body Weight; Clofazimine; Dose-Response Relationship, Drug | 2014 |
Use of proton NMR spectroscopy in the toxicological evaluation of new anti-mycobacterial agents.
Topics: Animals; Antitubercular Agents; Body Weight; Clofazimine; Kidney; Liver; Liver Function Tests; Magne | 1995 |